Docoh
Loading...

CHRS Coherus Biosciences

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system.

Company profile

CHRS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
20 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 330.18M 330.18M 330.18M 330.18M 330.18M 330.18M
Cash burn (monthly) (positive/no burn) (positive/no burn) 9.97M 12.73M 62.67K (positive/no burn)
Cash used (since last report) n/a n/a 36.69M 46.85M 230.7K n/a
Cash remaining n/a n/a 293.49M 283.33M 329.95M n/a
Runway (months of cash) n/a n/a 29.4 22.3 5265.1 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Oct 21 McDavid Stilwell Common Stock Sell Dispose S No No 16.8003 3,507 58.92K 31,611
29 Sep 21 Healy James Common Stock, $0.0001 par value Sell Dispose S Yes No 16.12 286,076 4.61M 0
28 Sep 21 Healy James Common Stock, $0.0001 par value Sell Dispose S Yes No 17.17 48,329 829.81K 286,076
27 Sep 21 Healy James Common Stock, $0.0001 par value Sell Dispose S Yes No 18.06 100,150 1.81M 334,405
6 Jul 21 Anicetti Vincent R Common Stock Grant Acquire A No No 0 50,000 0 124,790
6 Jul 21 Anicetti Vincent R Stock Option Common Stock Grant Acquire A No No 13.63 150,000 2.04M 150,000
9 Jun 21 McDavid Stilwell Common Stock Buy Acquire P No No 13.4237 3,700 49.67K 35,118
8 Jun 21 Dennis M Lanfear Common Stock Sell Dispose S No No 13.5644 31,054 421.23K 493,258
8 Jun 21 Dennis M Lanfear Common Stock Option exercise Acquire M No No 0.4168 31,054 12.94K 524,312
8 Jun 21 Dennis M Lanfear Stock Option Common Stock Option exercise Dispose M No No 0.4168 31,054 12.94K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • Net product revenue for the three and six months ended June 30, 2021 was $87.6 million and $170.7 million, respectively, compared to $135.7 million and $251.9 million for the three and six months ended June 30, 2020, respectively. The decreases were primarily due to a decrease in the number of units of UDENYCA® sold and an increase in discounts and allowances incurred during the three and six months ended June 30, 2021.
  • Our net product revenue and market penetration may rise modestly in the second half of 2021 compared to the first half of the year, assuming the impact of the COVID-19 pandemic does not worsen, and subject to pricing trends in the overall pegfilgrastim market.
  • Cost of goods sold was $16.7 million and $24.2 million for the three and six months ended June 30, 2021, respectively, compared to $10.1 million and $17.0 million for the three and six months ended June 30, 2020, respectively. Cost of goods sold consists primarily of third-party manufacturing, distribution, overhead costs associated with the sale of UDENYCA® and a mid-single digit royalty cost on net product revenue to Amgen, which began on July 1, 2019 and will continue for five years from then. For the six months ended June 30, 2021 and 2020, a portion of the manufacturing costs for inventory were incurred prior to the regulatory approval of UDENYCA® and, therefore, were expensed as research and development costs prior to those periods. The cost basis of product sold that was expensed prior to approval, was $0 and $4.9 million for the three months ended June 30, 2021 and 2020, respectively and $3.3 million and $10.5 million for the six months ended June 30, 2021 and 2020, respectively. Had such inventories been valued at acquisition cost, it would have resulted in corresponding increases in cost of goods sold and corresponding decreases in gross margin prior to the three months ended June 30, 2021. All the inventory expensed prior to approval of UDENYCA® was fully utilized by March 31, 2021. 
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Astrazeneca, Bristol, constitutionality, deadly, Delta, Eli, facilitating, instructed, Lilly, Merck, partly, PPQ, reconsider, reinstatement, Squibb, unnecessary, variant, waiver, worsen
Removed: abatement, AMD, back, bifurcated, binding, bioactivity, borrowing, commenced, complying, counterparty, decreasing, degeneration, derived, double, endpoint, exclude, feet, Hedge, host, incremental, inseverable, instance, leased, macular, mandate, modification, moved, Northern, piece, positive, presidential, repealed, resubmission, space, square, straight, strain, substantively, surfaced, unconstitutional, USV, vehicle, wet, Wuhan